Innovent Biologics

OverviewSuggest Edit

Innovent Biologics,Inc. is a leading biopharmaceutical company in China focused on the discovery, development and manufacturing of complex, high-end biologics for both the Asian and global markets that meet EMA and FDA/cGMP standards. Innovent has an expanding biologics pipeline focused on oncology, inflammatory diseases and ophthalmology. Innovent's strategy is to advance its internal pipeline of proprietary biologic drugs and establish in/out-licensing agreements with global pharmaceutical/biotech companies. Because of its location and emphasis on quality, Innovent is able to leverage China's cost-efficient environment without compromising its world-class quality standards.
TypePrivate
Founded2011
HQFangshan Qu, CN
Websiteinnoventbio.com

Latest Updates

Employees (est.) (Jun 2021)642(+5%)
Cybersecurity ratingCMore

Innovent Biologics Office Locations

Innovent Biologics has an office in Fangshan Qu
Fangshan Qu, CN (HQ)
Dong Ping Jie
Show all (1)

Innovent Biologics Financials and Metrics

Summary Metrics

Founding Date

2011

Innovent Biologics total Funding

$560 m

Innovent Biologics latest funding size

$150 m

Time since last funding

3 years ago

Innovent Biologics investors

Innovent Biologics's latest funding round in April 2018 was reported to be $150 m. In total, Innovent Biologics has raised $560 m
Show all financial metrics

Innovent Biologics Cybersecurity Score

Cybersecurity ratingPremium dataset

C

71/100

SecurityScorecard logo

Innovent Biologics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

Innovent Biologics Online and Social Media Presence

Embed Graph

Innovent Biologics News and Updates

Innovent Biologics and AnHeart Therapeutics Jointly Announce Exclusive License Agreement for Taletrectinib in Greater China

SAN FRANCISCO and SUZHOU, China, May 31, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major...

CMAB Biopharma Congratulates Partner Innovent Biologics on FDA Clearance of IND Application of its COVID-19 Antibody Project

SUZHOU, China, March 2, 2021 /PRNewswire/ -- CMAB Biopharma (Suzhou) Inc ("CMAB") congratulates its partner Innovent Biologics, Inc ("Innovent") (1801.HK) on the U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for its antibody candidate...

Innovent Biologics Announces to Host 2020 Virtual R&D Day on November 10th

SAN FRANCISCO and SUZHOU, China, Sept. 28, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other...

Innovent Biologics and Lilly Jointly Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Patients with Relapsed/Refractory Classic Hodgkin's Lymphoma

SUZHOU, China, May 31, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines, jointly announced with Eli Lilly and Company (Lilly) (NYSE: LLY) the research...

Innovent Biologics and Lilly Jointly Announced the Pivotal Clinical Study Results of TYVYT® (Sintilimab Injection) in the Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

SUZHOU, China, May 31, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines, jointly announced with Eli Lilly and Company (Lilly) (NYSE: LLY) the results of...

Innovent Biologics Announces FDA Acceptance of NDA for Pemigatinib in Patients with Previously Treated, Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

SUZHOU, China, Dec. 1, 2019 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent" or "the Company") (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases,...
Show more

Innovent Biologics Frequently Asked Questions

  • When was Innovent Biologics founded?

    Innovent Biologics was founded in 2011.

  • How many employees does Innovent Biologics have?

    Innovent Biologics has 642 employees.

  • Who are Innovent Biologics competitors?

    Competitors of Innovent Biologics include Roivant Sciences, Legend Biotech and Sansheng Biological Technology.

  • Where is Innovent Biologics headquarters?

    Innovent Biologics headquarters is located at Dong Ping Jie, Fangshan Qu.

  • Where are Innovent Biologics offices?

    Innovent Biologics has an office in Fangshan Qu.

  • How many offices does Innovent Biologics have?

    Innovent Biologics has 1 office.